https://pharmoniq.com/news/fda-approves-bizengri-nrg1-fusion-cholangiocarcinoma PharmoniQ en 2026-05-12T08:47:02.416Z FDA Approves Bizengri for Ultra-Rare Bile Duct Cancer Subtype FDA approval, cholangiocarcinoma, precision oncology, rare disease, biomarker therapy https://pharmoniq.com/news/pharmacy-quality-rewards-program-value-based-care-transformation PharmoniQ en 2026-05-11T14:10:49.048Z Pharmacy Quality Rewards Program Signals Major Shift to Value-Based Care value-based-care, pharmacy-reimbursement, quality-metrics, healthcare-policy, clinical-pharmacy https://pharmoniq.com/news/solgar-salmonella-recall-fda-adverse-event-reporting-failure PharmoniQ en 2026-05-10T14:10:49.012Z Solgar Recalls Products Over Salmonella; FDA Cites Reporting Failures Solgar, salmonella, product recall, adverse events, FDA compliance